

- **Name:** Jaewon Hyung
 - **Current Position & Affiliation:** Assistant professor, Department of Oncology,
Asan Medical Center University of Ulsan
College of Medicine
 - **Country:** Korea
-

• **Educational Background:**

2009. 3 – 2011. 2 Pre-Medicine
University of Ulsan College of Medicine
Seoul, Korea

2011. 3 – 2015. 2 Medical Degree
University of Ulsan College of Medicine
Seoul, Korea

2018. 3 – 2020. 2 Master of Science
University of Ulsan College of Medicine
Seoul, Korea

• **Professional Experience:**

2024.3 – 2025.02 Attending staff, full time clinical instructor

GI cancer team & Lymphoma and Myeloma program
Department of Oncology, Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

2025.3 – Assistant Professor

GI cancer team & Lymphoma and Myeloma program
Department of Oncology, Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

• Professional Organizations:

• Main Scientific Publications:

1. Jeongryul Ryu, Jaewon Hyung (Co-first), Sangwon Han, Jae Ho Jeong et al. Impact of 18F-FES PET/CT on clinical decisions in the management of recurrent or metastatic breast cancer. *Journal of Nuclear Medicine* 2024
2. Hyung J, Kim HD, GH Kim et al. Clinical outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment. *Cancer Research and Treatment*. 2023 Nov.
3. Hyung J, Cho H, Kim HD et al. DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial. *Gastric Cancer*. 2023 Oct.
4. Jaewon Hyung, Sae Byul Lee, Jisun Kim, et al. 21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer. *Int J Cancer*. 2023 Sep.
5. Jaewon Hyung, Hyung-Don Kim, Min-Hee Ryu, et al. GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-Assessment for Initially HER2 Negative Advanced Gastric Cancer Patients After Progression on First-Line Treatment. *Cancer Res Treatment*. 2023 Jun.
6. Changhoon Yoo, Jaewon Hyung, Stephen L. Chan, et al. Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma. *Liver Cancer*.
7. J Hyung, J Y Lee, J E Kim, et al. Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis. *ESMO Open*. 2023 Jun;8(3):101583.
8. Dong-Hoon Lim, Hyunseok Yoon, Kyu-Pyo Kim, Baek-Yeol Ryoo, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, Jaewon Hyung, Changhoon Yoo. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection. *Cancer Res Treat*. 2023 Oct;55(4):1313-1320.
9. Jaewon Hyung, Ilhwan Kim, Kyu-Pyo Kim, et al. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial. *JAMA Oncol*. 2023 May;9(5):692-699.
10. J Hyung, H Lee, H jin, et al. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. *ESMO Open*. 2022 Jun;7(3):100484.
11. Jaewon Hyung, Eun Jeong Cho, Jihun Kim, et al. Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer. *Cancer Res Treat*. 2022 Oct;54(4):1175-1190.
12. Jaewon Hyung, Tae Won Kim. The Asian Approach to the Management of Gastrointestinal Cancer Patients During the COVID-19 Pandemic Era. *Clin Colorectal Cancer*. 2020 Sep;19(3):151-152
13. Jaewon Hyung, Jung Yong Hong, Dok Hyun Yoon, et al. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. *Ann Hematol*. 2019;98(7):1657-1664.

